Dr Jane Warwick is Associate Professor in Clinical Trials Statistics and Head of Statistics at Warwick Clinical Trials Unit (WCTU), Warwick Medical School, University of Warwick. She has over 20 years’ experience in medical statistics, epidemiology and clinical trials. She obtained a BSc in Statistics (2.1) from the University of Birmingham (1987) and a PhD (thesis entitled “Selecting tuning parameters in minimum distance estimators”, funded by an Open University Studentship, supervisor Professor M.C. Jones) from the Department of Mathematics and Statistics at the Open University (2002). Her first post in medical statistics was at the Cancer Research Campaign Clinical Trials Unit at the University of Birmingham where she specialised in gynaecological oncology and developed a particular interest in ovarian cancer. After completing her PhD she joined the Cancer Research UK Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, where for ten years she worked with Professor Stephen Duffy on the evaluation of breast screening programmes and breast cancer aetiology and with Professor Jack Cuzick on breast cancer prevention and models to predict breast cancer risk. Much of her recent research has been on mammographic breast density and biomarkers but she is keen to become involved in other disease areas and has for many years been a reviewer for the NIHR EME and HTA programmes. Aside from leading the statistics team within WCTU she works with the CTU Director and other researchers to further develop Warwick CTU’s portfolio of pragmatic clinical trials and related statistical research studies. In 2014 she was awarded the Translational Cancer Research Prize for her contribution to the IBIS team (led by Prof Jack Cuzick QMUL), specifically the design and analysis of the mammographic density sub-studies and the development of the methodology for incorporating mammographic density into the IBIS breast cancer risk evaluation model. Her research interests include the evaluation of breast screening programmes, breast cancer aetiology, breast cancer prevention, models to predict breast cancer risk (in particular how to include mammographic breast density and biomarkers along with classic risk factors), gynaecological oncology and the use of frailty indices as a measure of general health, biological ageing and prognosis in the very elderly.